Company Description
ADARx Pharmaceuticals is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases.
We are focused on advancing and expanding our pipeline of highly potent, selective and durable siRNA, or small interfering RNA, therapeutic candidates, including three clinical-stage programs and two advanced preclinical programs.
Our three clinical-stage therapeutic candidates, each of which targets hepatic tissues, are being evaluated for the treatment of complement-mediated diseases, hereditary angioedema (HAE) and thrombotic diseases.
In addition, we are utilizing our CTD technology to expand beyond hepatic delivery into extrahepatic tissues, with two programs in or advancing to the investigational new drug application (IND)-enabling stage targeting adipose (obesity) and neurons (neurodegenerative diseases including Alzheimer’s).
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 100 |
| CEO | Zhen Li, Ph.D. |
Contact Details
Address: 5871 Oberlin Drive, Suite 200 San Diego, CA 92121 United States | |
| Phone | (877) 232-7974 |
| Website | adarx.com |
Stock Details
| Ticker Symbol | ADRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1802369 |
| Employer ID | 84-4145188 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Zhen Li, Ph.D. | President, Chief Executive Officer and Director |
| Ryan Fisk, M.B.A. | Chief Financial Officer and Chief Business Officer |
| A. Robert MacLeod, Ph.D. | Chief Scientific Officer |
| Rui Zhu, Ph.D. | Chief Technology Officer |
| Robert Ackles | Chief People Officer |
| Erez Chimovits, M.B.A. | Interim Chairman |
| Ting Feng, Ph.D. | Director |
| Simeon George, M.D., M.B.A. | Director |
| Carl L. Gordon, Ph.D., CFA | Director |
| Ying Huang, Ph.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 14, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Sep 4, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jul 31, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jun 22, 2026 | DRS | [Cover] Draft Registration Statement |
| Aug 10, 2023 | D | Notice of Exempt Offering of Securities |
| Jan 26, 2023 | D | Notice of Exempt Offering of Securities |
| Aug 17, 2021 | D | Notice of Exempt Offering of Securities |
| May 24, 2021 | D | Notice of Exempt Offering of Securities |
| Nov 17, 2020 | D | Notice of Exempt Offering of Securities |
| Aug 7, 2020 | D | Notice of Exempt Offering of Securities |